Pioglitazone on Pancreatic Steatosis and Bone Health

Completed · Not applicable · Has a placebo group

Conditions studied: Obesity, Type 2 Diabetes

In brief

Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on pancreatic fat content and bone turnover markers.

Key facts

Study ID

NCT00855010

Run by

University of Texas Southwestern Medical Center

People needed

42

Starts

2009-02-01

Expected to finish

2013-12-01

Last updated by the study team

2017-12-13

Who can join

Age: 21 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Fat level in the pancreas above 4% (measurement done by us with an MRI)
• English speaker
• over 21 years old

You may not qualify if…

• contraindication to MRI
• anemia
• pregnancy or desire to conceive
• use of unapproved medications
• prior pancreatic disease
• use of more then 2 alcoholic drinks every day

Where it is running

• UT Southwestern Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.